Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis
- PMID: 8258230
- DOI: 10.1007/BF02231572
Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis
Abstract
Tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF), all of endothelial origin and active in the haemostasis, were analysed in 74 patients with rheumatoid arthritis. The concentrations were related to extra-articular disease and to the incidence of thromboembolic events (TE) registered in a 2-year follow-up period. Patients with extra-articular disease had a significant increase in PAI-1 activity and reduced tPA release in the venous occlusion test. von Willebrand factor, PAI-1 and also haptoglobin and triglycerides were significantly increased in the group of patients who later suffered from TE. In a multiple regression model, in which cholesterol, triglycerides and lipoprotein (a) showed significant association with TE, vWF had the strongest additive explanatory value. No distinct acute phase pattern of PAI-1 was found in any patient subgroup.
Similar articles
-
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23. doi: 10.1161/01.atv.20.8.2019. Arterioscler Thromb Vasc Biol. 2000. PMID: 10938026
-
The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.Scand J Rheumatol. 2014;43(4):259-64. doi: 10.3109/03009742.2013.877158. Epub 2014 Apr 2. Scand J Rheumatol. 2014. PMID: 24689997
-
Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.Thromb Res. 2010 Feb;125(2):e46-50. doi: 10.1016/j.thromres.2009.08.010. Epub 2009 Sep 16. Thromb Res. 2010. PMID: 19762071
-
Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.Microvasc Res. 2021 Nov;138:104224. doi: 10.1016/j.mvr.2021.104224. Epub 2021 Jul 15. Microvasc Res. 2021. PMID: 34273359 Free PMC article.
-
Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.J Thromb Thrombolysis. 2001 May;11(3):183-93. doi: 10.1023/a:1011955018052. J Thromb Thrombolysis. 2001. PMID: 11577256 Review.
Cited by
-
Cardiovascular involvement in autoimmune diseases.Biomed Res Int. 2014;2014:367359. doi: 10.1155/2014/367359. Epub 2014 Jul 22. Biomed Res Int. 2014. PMID: 25177690 Free PMC article. Review.
-
Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study.Ann Rheum Dis. 2002 Mar;61(3):242-6. doi: 10.1136/ard.61.3.242. Ann Rheum Dis. 2002. PMID: 11830430 Free PMC article.
-
Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.Clin Rheumatol. 2013 Sep;32(9):1357-64. doi: 10.1007/s10067-013-2283-6. Epub 2013 May 15. Clin Rheumatol. 2013. PMID: 23673438
-
Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis.Front Cardiovasc Med. 2022 Oct 24;9:1012661. doi: 10.3389/fcvm.2022.1012661. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36352850 Free PMC article. Review.
-
Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation.Rheumatol Int. 2005 May;25(4):241-5. doi: 10.1007/s00296-004-0438-0. Epub 2004 Jul 31. Rheumatol Int. 2005. PMID: 15290086
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous